RECRUITING

Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial

Description

A behavioral trial aimed at helping patients identify what matters most to them and is part of a larger effort to pivot from disease-oriented care to whole-person care.

Conditions

Peripheral Neuropathy Due to Chemotherapy
Talk to us

Related Conditions:

Peripheral Neuropathy Due to Chemotherapy

Study Overview

On this page

Study Details

Study overview

A behavioral trial aimed at helping patients identify what matters most to them and is part of a larger effort to pivot from disease-oriented care to whole-person care.

Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial

Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial

Condition
Peripheral Neuropathy Due to Chemotherapy
Intervention / Treatment

-

Contacts and Locations

Houston

The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Provision of signed and dated electronic informed consent form
  • * Stated willingness to comply with all study procedures and availability for the duration of the study
  • * Age 18 or older.
  • * Documented diagnosis of chemotherapy-induced peripheral neuropathy meeting the following criteria: 1) onset associated with timing of neurotoxic chemotherapy and 2) symptomatic reports of peripheral neuropathy.
  • * Access to smartphone and internet for participating in a technology-based intervention
  • * Upcoming in-person appointment in the Main Hospital Pain Management Clinic 4-6 weeks from the consent date.
  • * English-speaking
  • * Pain or bothersome symptoms present most days of the week at an average of ≥4/10 on the Numeric Rating Scale for the past 3 months
  • * No longer receiving cancer treatment or has been on stable maintenance treatment for the past 3 months.
  • * Resides in the Houston Metroplex
  • * A score ≤7 on the validated Six Item Cognitive Impairment Test (6CIT) for unimpaired cognition
  • * Provision of signed and dated electronic informed consent form
  • * Stated willingness to comply with all study procedures and availability for the duration of the study
  • * Age 18 or older.
  • * Documented diagnosis of chemotherapy-induced peripheral neuropathy meeting the following criteria: 1) onset associated with timing of neurotoxic chemotherapy and 2) symptomatic reports of peripheral neuropathy.
  • * Access to smartphone and internet for participating in a technology-based intervention
  • * Upcoming in-person appointment in the Main Hospital Pain Management Clinic 4-6 weeks from the consent date.
  • * English-speaking
  • * Pain or bothersome symptoms present most days of the week at an average of ≥4/10 on the Numeric Rating Scale for the past 3 months
  • * No longer receiving cancer treatment or has been on stable maintenance treatment for the past 3 months.
  • * Resides in the Houston Metroplex
  • * A score ≤7 on the validated Six Item Cognitive Impairment Test (6CIT) for unimpaired cognition

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

M.D. Anderson Cancer Center,

Alice Ye, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2027-08-31